Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 3, 1999 (53-week fiscal year)
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of blood. The company operates as a single segment focused on surgical blood salvage, blood component therapy, plasma collection, and automated red cell collection.
Key Financial Metrics
| Metric (in thousands) | Fiscal 1999 | Fiscal 1998 |
|---|---|---|
| Net Revenues | $282,145 | $285,762 |
| Gross Profit | $133,502 | $135,755 |
| Gross Margin | 47.3% | 47.5% |
| Operating Income | $31,628 | $6,412 |
| Net Income (Continuing Ops) | $21,179 | $601 |
| Net Income (Total) | $21,077 | $(24,772) |
| Diluted EPS | $0.784 | $(0.932) |
| Cash from Operating Activities | $51,101 | $32,096 |
| Total Debt | $59,171 | $71,054 |
| Working Capital | $162,188 | $112,792 |
Material Changes vs. Prior Period
- Revenue Trend: Net revenues decreased 1.3% to $282.1 million. However, at constant currency, revenues increased 3.3%. Disposable sales (88% of revenue) grew 7.6% at constant currency, while equipment sales declined 36.0% due to a shift toward leasing and the absence of large one-time equipment shipments in 1998.
- Profitability Surge: Operating income increased significantly to $31.6 million from $6.4 million. This improvement was driven by gross profit enhancements from cost-saving initiatives (CORE Program) and the absence of the $24.5 million non-recurring restructuring charge recorded in fiscal 1998.
- Discontinued Operations: The company completed the divestiture of its Blood Bank Management Services (BBMS) business. In 1998, this segment contributed a significant loss; in 1999, the loss was minimal ($102k) as the assets were sold for $5.3 million in cash proceeds.
- Liquidity: Cash and cash equivalents increased from $21.8 million to $56.3 million. Net debt decreased by $46.4 million to $2.9 million.
Guidance, Outlook, and Risks
- Strategic Initiatives: The company is focusing on the "CORE" program to streamline operations and reduce costs. It is also expanding into the red blood cell apheresis market and revitalizing R&D with new products like the Superlite mobile collection system.
- Market Outlook: Management expects the annualized tax rate for fiscal 2000 to decrease to 32% from 35% due to changes in Japanese statutory rates and foreign sales corporation benefits.
- Year 2000 Compliance: The company estimates total compliance costs between $2.5 million and $3.3 million. While internal systems are largely compliant, risks remain regarding third-party vendor readiness and potential supply chain disruptions.
- Foreign Exchange: Over two-thirds of revenues are generated outside the U.S. A strengthening U.S. dollar adversely affects results. The company uses forward contracts to hedge firm sales commitments.
- Regulatory Risks: Products are subject to FDA and international regulations. Delays in approvals or changes in regulations could impact the business.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the single Japanese customer, which accounted for 20.6% ($72.9 million) of total sales in 1999.
- Equipment Sales Volatility: Confirm the sustainability of revenue given the 36% drop in equipment sales and the shift toward leasing models.
- Year 2000 Contingency: Assess the adequacy of the contingency plan regarding critical vendors and supply chain continuity post-January 1, 2000.
- Debt Covenants: Review the status of the $40 million Senior Notes, specifically the make-whole provision ($2.7 million) and the waiver regarding the $200 million stockholders' equity covenant.
- Discontinued Operations: Ensure all liabilities related to the divested blood bank operations have been fully resolved and no further reserves are required.